Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Solasia Pharma K.K. (4597.T)
Tokyo, JP
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.33% | -9.38% | -23.68% | -3.33% | -12.12% | +3.57% | -6.45% | -35.56% | -77.52% | -87.82% | -87.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+35.8% ★ Q1'26: -76.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+62.2% ★ Q1'26: +14.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-197.4% Q1'26: -1,050.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-200.2% Q1'26: -5,083.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-163.9% Q1'26: -542.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+19.5% Q1'26: +23.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.19× Q1'26: -0.07× (vs Q1'25)
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
410.85M
est: 433.00M (-5.1%)
|
318.00M
est: 346.00M (-8.1%)
|
1.31B
est: 1.19B (+9.8%)
|
454.00M
est: 2.56B (-82.3%)
|
559.00M
est: 600.00M (-6.8%)
|
1.09B
est: 1.15B (-5.0%)
|
617.00M
est: 1.79M (+34,369.3%)
|
316.00M
est: 1.36B (-76.8%)
|
429.00M
est: 1.26B (-66.0%)
|
1.92B
1.92B – 1.92B
+52.4% YoY
|
2.84B
2.84B – 2.84B
+47.8% YoY
|
3.65B
3.65B – 3.65B
+28.5% YoY
|
5.26B
5.26B – 5.26B
+44.3% YoY
|
| EBITDA |
-1.01B
est: -433.00M (-133.1%)
|
-2.27B
est: -346.00M (-554.9%)
|
-1.29B
est: -1.19B (-7.8%)
|
-2.82B
est: -2.56B (-10.1%)
|
-1.92B
est: -600.00M (-220.7%)
|
-1.20B
est: -1.15B (-3.9%)
|
-639.00M
est: -1.79M (-35,598.3%)
|
-796.00M
est: -1.36B (+41.5%)
|
-822.00M
est: -1.26B (+34.8%)
|
-1.92B
-1.92B – -1.92B
-52.4% YoY
|
-2.84B
-2.84B – -2.84B
-47.8% YoY
|
-3.65B
-3.65B – -3.65B
-28.5% YoY
|
-5.26B
-5.26B – -5.26B
-44.3% YoY
|
| EBIT |
-1.01B
est: -433.00M (-133.2%)
|
-2.42B
est: -346.00M (-599.1%)
|
-1.76B
est: -1.19B (-47.6%)
|
-3.32B
est: -2.56B (-29.5%)
|
-2.42B
est: -600.00M (-303.2%)
|
-1.73B
est: -1.15B (-50.3%)
|
-1.14B
est: -1.79M (-63,531.3%)
|
-991.00M
est: -1.36B (+27.1%)
|
-859.00M
est: -1.26B (+31.8%)
|
-1.92B
-1.92B – -1.92B
-52.4% YoY
|
-2.84B
-2.84B – -2.84B
-47.8% YoY
|
-3.65B
-3.65B – -3.65B
-28.5% YoY
|
-5.26B
-5.26B – -5.26B
-44.3% YoY
|
| Net Income |
-1.01B
est: -4.49B (+77.6%)
|
-2.42B
est: -7.09B (+65.9%)
|
-1.87B
est: -5.48B (+66.0%)
|
-4.13B
est: 59.61M (-7,023.2%)
|
-2.48B
est: -3.72B (+33.3%)
|
-2.55B
est: -2.66B (+4.3%)
|
-1.11B
|
-1.94B
est: -997.57M (-94.6%)
|
-876.00M
est: -617.54M (-41.9%)
|
-475.03M
-475.03M – -475.03M
+23.1% YoY
|
-95.01M
-95.01M – -95.01M
+80.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
646.49M
est: 1.57B (-58.7%)
|
908.00M
est: 1.25B (-27.5%)
|
1.39B
est: 4.32B (-67.7%)
|
1.14B
est: 9.26B (-87.7%)
|
1.45B
est: 2.17B (-33.1%)
|
974.00M
est: 4.16B (-76.6%)
|
573.00M
est: 6.48M (+8,749.1%)
|
567.00M
est: 2.07B (-72.6%)
|
600.00M
est: 1.92B (-68.7%)
|
2.92B
2.92B – 2.92B
+52.4% YoY
|
4.32B
4.32B – 4.32B
+47.8% YoY
|
5.55B
5.55B – 5.55B
+28.5% YoY
|
8.01B
8.01B – 8.01B
+44.3% YoY
|
| EPS |
-12.24
est: -22.60 (+45.8%)
|
-25.98
est: -35.70 (+27.2%)
|
-17.75
est: -27.60 (+35.7%)
|
-35.16
est: 0.30 (-11,820.0%)
|
-19.04
est: -18.70 (-1.8%)
|
-16.76
est: -13.40 (-25.1%)
|
-6.61
|
-9.77
est: -4.20 (-132.6%)
|
-3.69
est: -2.60 (-41.9%)
|
-2.00
-2.00 – -2.00
+23.1% YoY
|
-0.40
-0.40 – -0.40
+80.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.02% | 135.0K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fumiko Nagahama | Head of Product Development Division | — | — |
| Hikaru Osawa | Head of Production Management Division | — | — |
| Kozo Yao | Head of Business Development | — | — |
| Toshio Miyashita | Chief Financial Officer, Head of Management Headquarters & Director | — | male |
| Wataru Kobayashi | Head of Reliability Assurance Division | — | — |
| Yasuaki Manabe | Head of Marketing Division | — | — |
| Yasumitsu Shimada | Accounting Manager | — | — |
| Yoshihiro Arai | President, Chief Executive Officer & Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4597.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
